trial · primary record
Zanzalintinib
Meningioma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2029-09-30 |
| Primary endpoint | Objective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT07428616 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:46.284Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07428616
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Zanzalintinib · compound